← All trials
NCT06866574
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 11, 2025
- Primary completion
- Sep 30, 2031
- Completion date
- Sep 30, 2031
- First posted
- Mar 10, 2025
- Last posted
- Jul 31, 2025
- Enrollment
- 9300
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Xiamen UniversityLead sponsor
- Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.Collaborator
- Fudan UniversityOfficial
- Xiamen UniversitySponsor investigator
- Government of ChinaOfficial
- Xiamen UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.